The trajectory of companies tied to Sildenafil's past presents a complex investment landscape. While the initial surge generated substantial gains, generic alternatives have significantly impacted revenue. Investing in connected pharmaceutical firms now requires a thorough assessment of proprietary rights , evolving medical trends , and the prospec